GLP-1 drugs show promise beyond diabetes – heart, kidneys, dementia, addiction

GLP-1 drugs, originally developed for type 2 diabetes and later used for obesity, are now being studied for a much wider range of conditions. Researchers are investigating their effectiveness in heart disease, kidney and liver conditions, sleep apnoea, dementia and addiction treatment. The drugs' therapeutic potential appears far broader than initially expected.